Indeed, in murine tumor models, treatment combined with ICI and IL-6 blockade was reported to lead to increased tumor shrinkage in vivo, with a higher density of CD4+/CD8+ effector T cells and reduction of Th17, macrophages, and myeloid cells within tumor tissues (Hailemichael et al., 2022). The gene discussed is IL6; the disease is neoplasm.